893 related articles for article (PubMed ID: 27363937)
1. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
2. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
3. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment.
Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT
Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348
[TBL] [Abstract][Full Text] [Related]
4. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor.
Yan Z; Wang F; Wen Z; Zhan C; Feng L; Liu Y; Wei X; Xie C; Lu W
J Control Release; 2012 Jan; 157(1):118-25. PubMed ID: 21827801
[TBL] [Abstract][Full Text] [Related]
5. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
[TBL] [Abstract][Full Text] [Related]
6. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Shmeeda H; Tzemach D; Mak L; Gabizon A
J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
[TBL] [Abstract][Full Text] [Related]
7. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
8. Liposomal co-delivery of omacetaxine mepesuccinate and doxorubicin for synergistic potentiation of antitumor activity.
Shim G; Lee S; Choi J; Lee S; Kim CW; Oh YK
Pharm Res; 2014 Aug; 31(8):2178-85. PubMed ID: 24562810
[TBL] [Abstract][Full Text] [Related]
9. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of an Epidermal Growth Factor Receptor-Targeted Doxorubicin-Peptide Conjugate: Toxicity, Biodistribution, and Efficacy in Mice.
Yang F; Ai W; Jiang F; Liu X; Huang Z; Ai S
J Pharm Sci; 2016 Feb; 105(2):639-649. PubMed ID: 26869425
[TBL] [Abstract][Full Text] [Related]
11. pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation.
Gheybi F; Alavizadeh SH; Rezayat SM; Hatamipour M; Akhtari J; Faridi Majidi R; Badiee A; Jaafari MR
J Pharm Sci; 2021 Dec; 110(12):3919-3928. PubMed ID: 34418455
[TBL] [Abstract][Full Text] [Related]
12. Robust, tumor-homing and redox-sensitive polymersomal doxorubicin: A superior alternative to Doxil and Caelyx?
Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2016 Oct; 239():149-58. PubMed ID: 27569664
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.
Yuan M; Qiu Y; Zhang L; Gao H; He Q
Drug Deliv; 2016 May; 23(4):1171-83. PubMed ID: 26036724
[TBL] [Abstract][Full Text] [Related]
15. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
16. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics evaluation of a thermosensitive chitosan based hydrogel containing liposomal doxorubicin.
Ren S; Dai Y; Li C; Qiu Z; Wang X; Tian F; Zhou S; Liu Q; Xing H; Lu Y; Chen X; Li N
Eur J Pharm Sci; 2016 Sep; 92():137-45. PubMed ID: 27388491
[TBL] [Abstract][Full Text] [Related]
18. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
19. Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-bearing mice.
Wang H; Zheng M; Gao J; Wang J; Zhang Q; Fawcett JP; He Y; Gu J
Talanta; 2020 Feb; 208():120358. PubMed ID: 31816795
[TBL] [Abstract][Full Text] [Related]
20. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect.
Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X
Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]